- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03142360
Effect of Beraprost Sodium (Berasil) on Hemodialysis
There is no randomized control study to determine if the beneficial effects of beraprost sodium could improve the patency of arteriovenous fistula in hemodialysis patients. Therefore, this study is aimed to demonstrate the use of beraprost sodium can improve the patency of arteriovenous fistula in patients undergoing hemodialysis. This study is prospectively randomize controlled open-label trials in patients who newly made artificial arteriovenous fistula for hemodialysis. This study is a pilot study, and the target number of subjects is 60 in total, 30 in the treatment group and 30 in the control group.
After randomization, the treatment group takes a beraprost sodium for 6 months and the control group does not take placebo.
Treatment lasts for 6 months after dosing but continues until the patient changes the renal-replacement therapy method or falls under the exclusion criteria.
The patient should visit at 1, 3, and 6 months after arteriovenous graft surgery to check the access site after graft surgery. The doppler ultrasound test is performed to measure the access blood flow rate and patency of arteriovenous fistula.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Jung Tak Park, M.D., Ph.D.
- Phone Number: 82-2-2228-2281
- Email: jtpark@yuhs.ac
Study Locations
-
-
-
Seoul, Korea, Republic of, 120-752
- Recruiting
- Division of Nephrology, Department of Internal Medicine Yonsei University College of Medicine
-
Contact:
- Jung Tak Park, M.D., Ph,D
- Phone Number: 82-2-2228-2281
- Email: jtpark@yuhs.ac
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Patients who meet all of the following criteria
- Patient who newly made artificial arteriovenous fistula for hemodialysis
- Patients who agree to participate in the test and sign a consent form
- Patients who had diabetes
Exclusion Criteria:
- Patients under 18 years old, 80 years old or older
- Patients with a high risk of bleeding (hemophilia, capillary weakness, upper gastrointestinal bleeding, urinary tract bleeding, hemoptysis, vitreous hemorrhage, etc.)
- Women who are pregnant or have a possibility of pregnancy
- Platelet count ≤ 75000
- Patients taking anticoagulants or antithrombotics
- Patients with galactose intolerance, lactase deficiency or glucose-galactose malabsorption
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment group
Within two days after successful arteriovenous graft surgery, the treatment group is randomly assigned to start taking 120 mcg of Berasil.
|
Within two days after successful arteriovenous graft surgery, the treatment group is randomly assigned to start taking 120 mcg of Berasil.
|
No Intervention: Non-Treatment group
On the other hand, the control group does not take anything.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
AVF maturation rate
Time Frame: 3 months after arteriovenous graft surgery
|
Physiologic maturation of the AVF by the definition of AVF access blood flow ≥500mlL/min and AVF diameter ≥4mm at 3 months
|
3 months after arteriovenous graft surgery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
AVF maturation rate
Time Frame: 1 month after arteriovenous graft surgery
|
Physiologic maturation of the AVF by the definition of AVF access blood flow ≥500mlL/min and AVF diameter ≥4mm at a month
|
1 month after arteriovenous graft surgery
|
Hemodialysis performed rate
Time Frame: 3 months after arteriovenous graft surgery
|
3 months after arteriovenous graft surgery
|
|
AVF failure rate
Time Frame: 6 months after arteriovenous graft surgery
|
6 months after arteriovenous graft surgery
|
|
Bleeding events
Time Frame: 6 months after arteriovenous graft surgery
|
6 months after arteriovenous graft surgery
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- Lin CC, Yang WC, Chen MC, Liu WS, Yang CY, Lee PC. Effect of far infrared therapy on arteriovenous fistula maturation: an open-label randomized controlled trial. Am J Kidney Dis. 2013 Aug;62(2):304-11. doi: 10.1053/j.ajkd.2013.01.015. Epub 2013 Mar 6.
- Na KY, Kim DK, Kim SG, Lee YK, Lim CS. Effect of beraprost sodium on arterial stiffness in patients with type 2 diabetic nephropathy. Trials. 2013 Sep 2;14:275. doi: 10.1186/1745-6215-14-275.
- Dixon BS, Beck GJ, Vazquez MA, Greenberg A, Delmez JA, Allon M, Dember LM, Himmelfarb J, Gassman JJ, Greene T, Radeva MK, Davidson IJ, Ikizler TA, Braden GL, Fenves AZ, Kaufman JS, Cotton JR Jr, Martin KJ, McNeil JW, Rahman A, Lawson JH, Whiting JF, Hu B, Meyers CM, Kusek JW, Feldman HI; DAC Study Group. Effect of dipyridamole plus aspirin on hemodialysis graft patency. N Engl J Med. 2009 May 21;360(21):2191-201. doi: 10.1056/NEJMoa0805840.
- Vicil S, Erdogan S. Beraprost sodium, a prostacyclin (PGI) analogue, ameliorates lipopolysaccharide-induced cellular injury in lung alveolar epithelial cells. Turk J Med Sci. 2015;45(2):284-90. doi: 10.3906/sag-1401-108.
- Arai T. Long-term effects of beraprost sodium on arteriosclerosis obliterans: a single-center retrospective study of Japanese patients. Adv Ther. 2013 May;30(5):528-40. doi: 10.1007/s12325-013-0030-7. Epub 2013 Jun 8.
- Murakami M, Watanabe M, Furukawa H, Nakahara H. The prostacyclin analogue beraprost sodium prevents occlusion of bypass grafts in patients with lower extremity arterial occlusive disease: a 20-year retrospective study. Ann Vasc Surg. 2005 Nov;19(6):838-42. doi: 10.1007/s10016-005-7668-9.
- Sakao S, Tanabe N, Kasahara Y, Tatsumi K. Long-term survival of Japanese patients with pulmonary arterial hypertension treated with beraprost sodium, an oral prostacyclin analogue. Intern Med. 2014;53(17):1913-20. doi: 10.2169/internalmedicine.53.2573. Epub 2014 Sep 1.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 4-2017-0129
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Arteriovenous Fistula Patency
-
Medtronic EndovascularCompletedFistula | Arteriovenous Fistula | Arteriovenous Fistula Stenosis | Arteriovenous Fistula OcclusionNew Zealand, United States, Japan
-
University of VirginiaAstraZenecaCompletedEnd Stage Renal Disease | Vascular Access PatencyUnited States
-
MedtronicRecruitingFistula | Arteriovenous Fistula | Arteriovenous Fistula Stenosis | Arteriovenous Fistula OcclusionUnited States
-
Hospital General Universitario Gregorio MarañonSpanish Society of NephrologyCompletedArteriovenous Fistula Stenosis | Arteriovenous Fistula ThrombosisSpain
-
Ai PengRecruitingArteriovenous Fistula Flow Monitoring | Early Detection of Complications of Arteriovenous Fistula | VoiceprintChina
-
Rennes University HospitalTerminatedStenosis of Arteriovenous Dialysis FistulaFrance
-
Fundación Pública Andaluza Progreso y SaludCompletedArteriovenous Fistula Renal Dialysis Devices ObstructionSpain
-
Centre hospitalier de l'Université de Montréal...Biotronik Canada IncCompletedArteriovenous Graft | Arteriovenous FistulaeCanada
-
Henry Ford Health SystemAnalogic CorporationCompletedArteriovenous Fistula, CannulationUnited States
-
National Taiwan University HospitalCompletedArteriovenous Fistula OcclusionTaiwan
Clinical Trials on Beraprost sodium (Berasil)
-
Seoul National University HospitalAstellas Pharma Korea, Inc.UnknownDiabetic NephropathyKorea, Republic of
-
Shenzhen People's HospitalRecruitingEssential HypertensionChina
-
Toray Industries, IncCompletedRenal ImpairmentJapan
-
Lung Biotechnology PBCCompletedPulmonary Arterial HypertensionUnited States, Belgium, Czechia, Germany, Ireland, Romania
-
Lung Biotechnology PBCCompletedPulmonary Arterial HypertensionUnited States, Ireland, Belgium
-
Lung Biotechnology PBCCompletedPulmonary Arterial HypertensionUnited States, Belgium, Czechia, Germany, Ireland, Romania
-
Lung Biotechnology PBCCompletedPulmonary Arterial HypertensionUnited States, Belgium, Ireland
-
The Affiliated Hospital of Xuzhou Medical UniversityUnknown
-
Lung Biotechnology PBCWithdrawn
-
Lung Biotechnology PBCCompletedPulmonary Arterial HypertensionUnited States, Israel